The integration of immunotherapy into the treatment of triple-negative breast cancer (TNBC) has fundamentally shifted the prognosis for many patients, offering higher rates of pathologic complete response and improved survival. However, this clinical victory introduces a complex modern variable: the risk of immune-related adverse events (irAEs). Because these toxicities can manifest as systemic inflammation or endocrine failure, supporting safe surgery in TNBC through early management of immune-related adverse events has become a critical priority for multidisciplinary oncology teams.
While immune checkpoint inhibitors like pembrolizumab are designed to activate the body’s immune system to attack cancer cells, they can inadvertently trigger the immune system to attack healthy organs. In the neoadjuvant setting—where therapy is administered before surgery to shrink a tumor—these side effects are not merely quality-of-life issues. They can become surgical roadblocks, delaying curative-intent operations and complicating the perioperative window.
A retrospective study published in the journal Cancers by Jeeyeon Lee and colleagues highlights the real-world frequency of these events. Analyzing 82 patients with stage II-III TNBC who received a KEYNOTE-522–based regimen—combining pembrolizumab with paclitaxel, carboplatin and later doxorubicin and cyclophosphamide—the researchers found that irAEs occurred in 72% of patients.
The Hidden Risks of Endocrine Dysfunction
Not all immunotherapy side effects are immediately obvious. While dermatologic reactions like rash and dermatitis, as well as myalgia, were among the most frequently reported events, the most dangerous toxicities are often the “silent” ones. Endocrine dysfunctions, particularly those affecting the thyroid and adrenal glands, can remain asymptomatic until they reach a critical threshold, posing significant risks during general anesthesia.
Hypothyroidism is a primary concern for surgical teams. If left uncorrected, an underactive thyroid can lead to reduced cardiac output and cardiovascular instability. In the context of a major mastectomy or lymph node dissection, these factors increase the likelihood of anesthesia-related complications. The Lee study found that endocrine dysfunction was the leading cause of surgical delays, with some patients experiencing postponements of eight weeks or longer to achieve a euthyroid state (normal thyroid function) before proceeding to the operating room.
Commonly Observed Toxicities in TNBC Patients
The spectrum of irAEs varies widely, ranging from mild annoyances to severe systemic failures. The following table outlines the common toxicities observed in the study population:
| Toxicity Type | Common Manifestations | Clinical Impact |
|---|---|---|
| Dermatologic | Rash, Dermatitis | Generally low grade; manageable |
| Musculoskeletal | Myalgia | Symptom management required | Endocrine | Hypothyroidism, Hyperthyroidism | Significant risk of surgical delay |
| Gastrointestinal | Diarrhea, Colitis | Potential for poor oral intake |
| Hepatic | Elevated transaminases | Can lead to surgical postponement |
The Critical Window: Why Timing Matters
In metastatic cancer treatment, a delay in a drug cycle is often a manageable adjustment. However, in the neoadjuvant setting, the timeline is rigid. Surgery is intended to be the curative “closing” of the primary treatment phase. Any delay in this timeline can compromise the overall treatment strategy and potentially impact patient outcomes.
According to the study, 7.3% of patients experienced surgical delays. These were primarily driven by grade 2 or higher toxicities. Beyond thyroid issues, delays were also attributed to severe systemic fatigue, poor oral intake, and hepatotoxicity. This underscores the necessity of a proactive monitoring strategy rather than a reactive one.
The Frontline Role of Oncology Nursing
Because many irAEs begin as vague symptoms—extreme tiredness, a mild itch, or a change in bowel habits—oncology nurses are often the first to detect a problem. When a patient calls a triage line to report these changes, the nurse is the first line of defense in identifying a potential toxicity before it escalates into a surgical crisis.
Effective management relies on three pillars of nursing intervention:
- Vigilant Monitoring: Coordinating routine laboratory assessments, specifically thyroid function and adrenal axis evaluation (cortisol production), to catch asymptomatic endocrine failure.
- Patient Education: Training patients to recognize and immediately report “red flag” symptoms, such as shortness of breath (which may indicate pneumonitis) or sudden gastrointestinal distress.
- Interdisciplinary Coordination: Acting as the communication hub between oncology, surgery, anesthesia, and endocrinology to ensure the patient is medically optimized for the operating room.
The ability to catch a thyroid hormone deficiency early allows for hormone replacement therapy to begin weeks before the scheduled surgery, potentially preventing the eight-week delays noted in the retrospective data.
Looking Ahead: Refining the Neoadjuvant Path
While the study by Lee and colleagues was limited by its retrospective design and a relatively small sample size of 82 patients, it provides a vital real-world snapshot of the challenges facing TNBC patients. As immunotherapy becomes a standard of care for stage II-III disease, the medical community is moving toward more standardized screening protocols to minimize perioperative risks.
The next phase of clinical focus will likely involve refining the timing of endocrine screenings and developing more precise guidelines for when a “grade 2” toxicity necessitates a surgical delay versus when it can be managed concurrently with perioperative care. Continuous monitoring and interdisciplinary communication remain the most effective tools for ensuring that the benefits of immunotherapy are not undermined by avoidable surgical complications.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should consult their healthcare provider for personalized treatment plans and symptom management.
We invite readers to share their experiences with immunotherapy management or ask questions in the comments below to help foster a broader conversation on cancer care coordination.
Keep reading
